Role of epoetins in beta-thalassemia minor patients with solid tumors undergoing chemotherapy: Results of a retrospective analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19600-19600
Author(s):  
H. J. Soto Parra ◽  
E. Medula ◽  
F. Latteri ◽  
G. Lavenia ◽  
P. Amadio ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Solid Tumors ◽  
Stage Iv ◽  
Beta Thalassemia ◽  
Second Line ◽  
Mean Values ◽  
Mild Anemia ◽  
Thalassemia Minor ◽  
Prospective Trials

19600 Background: β-Thalassemia minor (β-Tm) is the most common hereditary disorder in the Mediterranean region with a prevalence of 6% in Sicily. β-Tm is characterised by mild anemia (A). Therefore, we performed a retrospective analysis to evaluate the course of A in β-Tm pts with solid tumors (ST) undergoing chemotherapy (CT). Methods: β-Tm pts with ST were identified from our clinical record database [history and/or hemoglobin (Hb) A2 level > 3.3%]. Inclusion criteria were first-line or second-line CT after a CT-free interval of 6 mos. Exclusion criteria:concomitant radiotherapy (RT) , or previous RT to pelvic region, or active bleeding. Results: From July 2004 until the present day, 26 β-Tm pts with ST have been observed, and 23 fulfil the criteria of this analysis. The pt demography was as follows: median age, 56 years (range, 38–76 years); Males: 9 pts; PS 0/1: 19/4; stage IV: 10; types of cancers: breast 7, gastrointestinal 7, others 9; platinum containing regimen: 7. A was evaluated during first and second-line treatments in 19 and 4 pts, respectively. The mean values of Hb and the incidence of pts (%) with mild (from ≥10 and <12 gr/dl) or moderate (<10 gr/dl) A during CT, were as follows. No paradoxical effect of CT on the Hb level was observed. One pt received transfusions (Hb level, 7.8 gr/dl). Nine pts were treated with epoetin (darbepoetin alfa, 7 pts) and iron supplements due to worsening A (mean Hb value = 9 gr/dl ± 0.6): five pts experienced a ≥2 gr/dl increase in the Hb level at 8 weeks, one had >1 gr/dl, one had stable values = 9 gr/dl, and two pts had decreased values, i.e. < 8 gr/dl, and required transfusions. Conclusion: This analysis demonstrates that 70% of β-Tm pts with ST have mild or moderate A prior to CT. The A of β-Tm patients is worsened by CT and results in moderate A in 55% of the pts. Epoetins, particularly effectively ameliorate A when administered to pts with Hb levels of <10 gr/dl. This data suggests that epoetin treatment during CT may benefit β-Tm pts; however, prospective trials are required. No significant financial relationships to disclose. [Table: see text]

scholarly journals HBG2 -158 (C>T) polymorphism and its contribution to fetal hemoglobin variability in Iraqi Kurds with beta-thalassemia minor

2018 ◽  
Vol 10 (04) ◽  
pp. 370-373
Author(s):  
Dilan J. Albarawi ◽  
Amer A. Balatay ◽  
Nasir Al-Allawi
Keyword(s):  
High Performance ◽  
Fetal Hemoglobin ◽  
Minor Allele ◽  
Beta Thalassemia ◽  
Chromosome 11 ◽  
Hemoglobin Variability ◽  
Thalassemia Minor ◽  
Red Cell Indices ◽  
Different Populations

ABSTRACT PURPOSE: Hemoglobin (Hb) F% is increased in up to half of beta-thalassemia (β-thal) carriers. Several polymorphisms have been linked to such variability in different populations, including HBG2 - 158(C>T) (Xmn I polymorphism) on chromosome 11. To determine the role of this polymorphism in such variability among Iraqi Kurds, the current study was initiated. MATERIALS AND METHODS: A total of 102 consecutive patients diagnosed as β-thal minor were enrolled. The enrollees had their diagnosis based on peripheral blood counts and high-performance liquid chromatography to determine HbA2 and HbF. All enrollees had their DNA extracted by phenol-chloroform method and Xmn I polymorphism detected by restriction fragment length polymorphism-polymerase chain reaction. RESULTS: The mean age (standard deviation [SD]) of the 102 enrollees was 25.4 (14.0) years, and the enrollees included 48 males and 54 females. Xmn I polymorphism was identified in heterozygous state in 46 (45.1%) patients and in homozygous state in one patient (0.98%). Thus, the minor allele frequency of this polymorphism was 0.235 in the studied group. There were no significant differences in red cell indices and HbA2% in carriers of the minor allele compared to noncarriers, while HbF% and absolute HbF concentrations were significantly higher in the former subgroup (P = 0.032 and 0.014, respectively). This polymorphism's contribution to HbF variability was found to be 5.8% in the studied sample. Furthermore, those with HbF ≥2% were 3.2 folds more likely to carry the minor allele. CONCLUSIONS: Xmn I polymorphism is frequently encountered in Iraqi Kurds with β-thal minor, and it is significantly associated with higher fetal hemoglobin in these patients.

scholarly journals Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and Future

ONCOLOGY ◽  
2021 ◽  
pp. 311-319
Author(s):  
Neal McCall ◽  
Kristin Higgins
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ablative Therapies ◽  
Prospective Trials ◽  
Symptom Palliation

Historically, patients with stage IV non–small cell lung cancer (NSCLC) have been treated with chemotherapy alone, reserving local therapies for symptom palliation. However, evidence has accumulated that a subset of patients with oligometastatic NSCLC (OM-NSCLC) may benefit from local ablative therapies (LATs). In this article, we review the data that have formed the rationale for LAT, specifically radiotherapy, and the prospective trials that support its use in this population. Finally, we examine the evolving role of LAT in patients with OM-NSCLC in the context of immunotherapy and targeted therapies, as well as discuss ongoing clinical trials incorporating LAT in these patients.

Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4039-4039
Author(s):  
Ludmila Katherine Martin ◽  
Susan Michelle Geyer ◽  
Anissa Bingman ◽  
Mark M. Zalupski ◽  
Tanios S. Bekaii-Saab
Keyword(s):  
Pancreas Cancer ◽  
Stage Iv ◽  
Predictive Biomarker ◽  
Phase Iii ◽  
Phase Ii Studies ◽  
Prospective Phase ◽  
Prospective Trials ◽  
Phase Iii Studies ◽  
Background Phase

4039 Background: Phase III studies of B in unselected pts with APCA have demonstrated no improvement in outcome. Recent data suggest certain subsets of APCA patients may benefit from B. Lower b- alb results in a 15-20% increased rate of B clearance that may decrease exposure to B. The resulting clinical implications are not well understood. We evaluated the potential predictive and prognostic role of b-alb in pts with APCA receiving gemcitabine (G)-based tx with or without B. Methods: Relevant data were collected from 3 prospective phase II studies of G-based tx. Pts were grouped according to exposure to B (Gr 1) or no B (Gr 2) and by b-alb < 3.4 g/dL (< LLN) or > 3.4 g/dL (>LLN). Univariate and multivariate analyses of clinical outcome (OS, TTP) were conducted for each group and all pts. Results: 100 pts (46M, 54F) with median age 63 (range 28-82) were included. 94% had stage IV. Median b-alb was similar in both groups. Clinical outcomes by alb are outlined in the table. In Gr 1 but not Gr 2, b-alb > 3.4 g/dL was significantly associated with improved OS and TTP. For pts with b-alb >3.4 g/dL, maintenance of alb >3.4 g/dL throughout tx was significantly associated with improved survival in Gr 1 but not Gr 2. Multivariate analysis revealed significant association between alb > 3.4 and OS regardless of B status (p=0.004) although this was strongly influenced by the survival differential in Gr 1. Conclusions: APCA pts with b-alb > 3.4 g/dL appear to derive significant benefit from B and this benefit is most pronounced in pts who maintain alb > 3.4 g/dL throughout B tx. This finding was not observed in pts treated without B. b-alb > 3.4 g/dL including maintenance of alb > 3.4 g/dL during B tx may predict for improved efficacy of B in APCA. These findings require further investigation in larger prospective trials. [Table: see text]

scholarly journals The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis

2013 ◽  
pp. 1493
Author(s):  
Paul Zarogoulidis ◽  
Efimia Boutsikou ◽  
Kaid Darwiche ◽  
Lutz Freitag ◽  
Dionysios Spyratos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Retrospective Analysis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals The Role of Adjuvant Chemotherapy in Stage Ⅳ Hepatocellular Carcinoma Patients

2021 ◽  
Author(s):  
Quanhui Liao ◽  
Shaoxin Shen ◽  
Xijing Ma ◽  
Guisen Dai ◽  
Geng Lu ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Proportional Hazards ◽  
Stage Iv ◽  
Cox Proportional Hazards ◽  
Independent Factor ◽  
Cancer Specific Survival ◽  
Kaplan Meier ◽  
Prospective Trials

Abstract Background and objectives The purpose of the present study was to comprehensively analyze the prognostic value of adjuvant chemotherapy (CT) in stage IV HCC patients. Methods HCC patients were recognized in the Surveillance, Epidemiology and End Results (SEER) database. The effects of adjuvant CT on HCC patients were evaluated by Kaplan–Meier curves and multivariable Cox proportional hazards analyses. Results A total of 490 HCC patients were enrolled in this study and the median follow-up time was 2.69 months (range: 0–102 months). 34.3% (168) HCC patients received adjuvant CT, of which 58.6% (287) received local destruction, 25.5% (125) were partial resection and 15.9% (78) underwent liver transplantion. Multivariate analysis showed that chemotherapy (P <0.001), surgery (P <0.001), year at diagnosis (P = 0.004), grade (P <0.001) and fibrosis score (P = 0.039) were independent factor of cancer specific survival (CSS), and that chemotherapy (P <0.001), surgery (P <0.001), year at diagnosis (P = 0.005), grade (P <0.001) were independent factor of overall survival (OS). Survival curves confirmed that patients achieved an increased OS or CSS from adjuvant CT (P <0.05). Conclusions Our results concluded that compared to surgery alone, stage IV HCC patients could profit from adjuvant chemotherapy. High quality prospective trials are necessary to further confirm our results.

A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1053-1053 ◽  
Author(s):  
Carlos Henrique dos Anjos ◽  
Pedram Razavi ◽  
Joshua Herbert ◽  
Jodecy Colon ◽  
Kaitlyn Gill ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Metastatic Breast ◽  
Hormone Signaling ◽  
Second Line ◽  
Single Institution ◽  
Best Response ◽  
Prospective Trials ◽  
Tumor Sequencing ◽  
Clinical Paradigm ◽  
Line Setting

1053 Background: Sequential retreatment with endocrine therapy (ET) has been the clinical paradigm for ER+ MBC due to persistent dependence on hormone signaling. Recently CDK4/6i + ET have improved PFS and are routinely utilized in the first/second- line setting. Whether this paradigm of sequential retreatment holds for CDK 4/6i is unknown. To evaluate the potential benefit of CDK4/6i re-treatment we conducted this retrospective analysis. Methods: We identified ER+/HER2- MBC pts treated with ≥ 2 lines of CDK4/6i at our institution between 2015-2018. We categorized pts based on reason for discontinuation of their first CDK4/6i: cohort 1 – switch to alternate CDK4/6i due to toxicity; cohort 2 – retreatment with same CDK4/6i beyond progression with change of ET and cohort 3- switch to alternate CDK4/6i as monotherapy or with same or another ET. We analyzed pt demographics, imaging reports and time to subsequent therapy (TTST) for every CDK4/6i line for each cohort. If a pt received > 2 lines of CDK4/6i, then that pt was evaluated for every CDK4/6i exposure. Results: 135 pts received ≥ 2 lines of CDK4/6i treatment (Tx). Cohorts 1, 2 and 3 had 23, 43 pts and 84 pts respectively. In Cohort 2, 95% of pts received 2 subsequent CDK 4/6i + ET Tx; 56% had the second CDK4/6i in second-line met setting. TTST1 (1st CDK4/6i Tx) was 9.6m (95% CI 4.9 - 11 m), TTST2 (second CDK4/6i Tx) was 4.5m (95% CI 3.3 – 7.6 m) and 35% had TTST2 ≥ 24 weeks. For Cohort 3, 48% were retreated with a different CDK 4/6i in ≥ fifth-line. 51% received 2 subsequent CDK 4/6i Tx with 18% in second-line met setting. TTST1 was 9.6 m (95% CI 5.9 – 12 m), TTST2 was 4.4 m (95% CI 3.8 – 5.9 m) and 29% had TTST2 ≥ 24 weeks. In cohort 3, 29% (n=24) pts had PD as best response at the time of first CDK4/6i exposure but 29% (7/24) achieved a radiologic response to their second CDK4/6i Tx. Pts had tumor sequencing using MSK-IMPACT which will be correlated with TTST. Conclusions: This large single institution retrospective analysis suggests that retreatment with a CDK4/6i regimen should be evaluated in prospective trials. Additionally, despite PD as best response with the first CDK4/6i (palbociclib/ribociclib) regimen, a subset of pts had radiologic response to a subsequent abemaciclib-containing regimen, which is an hypothesis generating observation.

Social Representations and Commitment

2018 ◽  
Vol 23 (3) ◽  
pp. 233-249 ◽  
Author(s):  
Eric Bonetto ◽  
Fabien Girandola ◽  
Grégory Lo Monaco
Keyword(s):  
Social Representations ◽  
Social Representation ◽  
Second Line ◽  
Review Of The Literature ◽  
First Line ◽  
Research Perspectives ◽  
The Social ◽  
Bibliographic Search ◽  
English Articles

Abstract. This contribution consists of a critical review of the literature about the articulation of two traditionally separated theoretical fields: social representations and commitment. Besides consulting various works and communications, a bibliographic search was carried out (between February and December, 2016) on various databases using the keywords “commitment” and “social representation,” in the singular and in the plural, in French and in English. Articles published in English or in French, that explicitly made reference to both terms, were included. The relations between commitment and social representations are approached according to two approaches or complementary lines. The first line follows the role of commitment in the representational dynamics: how can commitment transform the representations? This articulation gathers most of the work on the topic. The second line envisages the social representations as determinants of commitment procedures: how can these representations influence the effects of commitment procedures? This literature review will identify unexploited tracks, as well as research perspectives for both areas of research.

Sign in / Sign up

Export Citation Format

Share Document